Expression of Interferon Lambda 4 Is Associated with Reduced Proliferation and Increased Cell Death in Human Hepatic Cells

Interferon lambda 4 (IFN-λ4) is a novel type-III interferon that can be generated only in individuals carrying a ΔG frame-shift allele of an exonic genetic variant (rs368234815-ΔG/TT). The rs368234815-ΔG allele is strongly associated with decreased clearance of hepatitis C virus (HCV) infection. Here, we further explored the biological function of IFN-λ4 expressed in human hepatic cells—a hepatoma cell line HepG2 and fresh primary human hepatocytes (PHHs). We performed live confocal imaging, cell death and proliferation assays, mRNA expression profiling, protein detection, and antibody blocking assays using transient and inducible stable in vitro systems. Not only did we observe significant intracellular retention of IFN-λ4 but also detected secreted IFN-λ4 in the culture media of expressing cells. Secreted IFN-λ4 induced strong activation of the interferon-stimulated genes (ISGs) in IFN-λ4-expressing and surrounding cells in transwell assays. Specifically, in PHHs, secreted IFN-λ4 induced expression of the CXCL10 transcript and a corresponding pro-inflammatory chemokine, IP-10. In IFN-λ4-expressing HepG2 cells, we also observed decreased proliferation and increased cell death. All IFN-λ4-induced phenotypes—activation of ISGs, decreased proliferation, and increased cell death—could be inhibited by an anti-IFN-λ4-specific antibody. Our study offers new insights into biology of IFN-λ4 and its possible role in HCV clearance.

[1]  S. Kakinuma,et al.  Impaired induction of interleukin 28B and expression of interferon λ 4 associated with nonresponse to interferon‐based therapy in chronic hepatitis C , 2015, Journal of gastroenterology and hepatology.

[2]  T. O'Brien,et al.  Reply: Subgroup Differences in Response to 8 Weeks of Ledipasvir/Sofosbuvir for Chronic Hepatitis C , 2015, Open forum infectious diseases.

[3]  V. Wong,et al.  Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease , 2015, Nature Communications.

[4]  D. Goldstein,et al.  Interferon-λ4 is a cell-autonomous type III interferon associated with pre-treatment hepatitis C virus burden. , 2015, Virology.

[5]  Z. Kutalik,et al.  Correction: Corrigendum: Reduced IFNλ4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes , 2014, Nature Communications.

[6]  D. Booth,et al.  Interferon- l rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease , 2015 .

[7]  Z. Kutalik,et al.  Reduced IFNλ4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes , 2014, Nature Communications.

[8]  T. O'Brien,et al.  Subgroup Differences in Response to 8 Weeks of Ledipasvir/Sofosbuvir for Chronic Hepatitis C , 2014, Open forum infectious diseases.

[9]  L. Prokunina-Olsson,et al.  IFN-λ4: the paradoxical new member of the interferon lambda family. , 2014, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[10]  M. Dennis,et al.  Selection on a Variant Associated with Improved Viral Clearance Drives Local, Adaptive Pseudogenization of Interferon Lambda 4 (IFNL4) , 2014, PLoS genetics.

[11]  L. Prokunina-Olsson,et al.  Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome. , 2014, The Journal of clinical investigation.

[12]  L. Prokunina-Olsson,et al.  IFNL4-ΔG genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin. , 2014, The Journal of infectious diseases.

[13]  Y. Maehara,et al.  Interferon‐lambda4 genetic polymorphism is associated with the therapy response for hepatitis C virus recurrence after a living donor liver transplant , 2014, Journal of viral hepatitis.

[14]  C. Rice,et al.  Interferon lambda alleles predict innate antiviral immune responses and hepatitis C virus permissiveness. , 2014, Cell host & microbe.

[15]  L. Prokunina-Olsson,et al.  Association of the IFNL4-ΔG Allele With Impaired Spontaneous Clearance of Hepatitis C Virus. , 2014, The Journal of infectious diseases.

[16]  Brien,et al.  Association of the IFNL 4-Δ G Allele With Impaired Spontaneous Clearance of Hepatitis C Virus , 2014 .

[17]  M. Imamura,et al.  Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C , 2014, Journal of Gastroenterology.

[18]  U. Spengler,et al.  Interferon-λ4 (IFNL4) Transcript Expression in Human Liver Tissue Samples , 2013, PloS one.

[19]  T. Pietschmann,et al.  Interferon lambda 4 signals via the IFNλ receptor to regulate antiviral activity against HCV and coronaviruses , 2013, The EMBO journal.

[20]  T. Liang,et al.  Current and future therapies for hepatitis C virus infection. , 2013, The New England journal of medicine.

[21]  A. Flaxman,et al.  Global epidemiology of hepatitis C virus infection: New estimates of age‐specific antibody to HCV seroprevalence , 2013, Hepatology.

[22]  Barbara Rehermann,et al.  A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus , 2013, Nature Genetics.

[23]  F. Marincola,et al.  HCV RNA levels in a multiethnic cohort of injection drug users: Human genetic, viral and demographic associations , 2012, Hepatology.

[24]  R A Knight,et al.  Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012 , 2011, Cell Death and Differentiation.

[25]  L. Prokunina-Olsson,et al.  A variant upstream of IFNL 3 ( IL 28 B ) creating a novel interferon gene IFNL 4 is associated with impaired clearance of hepatitis C virus , 2012 .

[26]  E. Fish,et al.  Interferon: current status and future prospects in cancer therapy. , 2011, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[27]  Mingli Liu,et al.  The emerging role of CXCL10 in cancer (Review). , 2011, Oncology letters.

[28]  Julia E. Vogt,et al.  Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. , 2011, Gastroenterology.

[29]  Shanchun Guo,et al.  The emerging role of CXCL 10 in cancer ( Review ) , 2011 .

[30]  Jacques Fellay,et al.  IL28B genotype is associated with differential expression of intrahepatic interferon‐stimulated genes in patients with chronic hepatitis C , 2010, Hepatology.

[31]  G. Los,et al.  Peroxisome Dynamics in Cultured Mammalian Cells , 2009, Traffic.

[32]  David B. Goldstein,et al.  Genetic variation in IL28B and spontaneous clearance of hepatitis C virus , 2009, Nature.

[33]  Jacques Fellay,et al.  Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance , 2009, Nature.

[34]  A. Neumann,et al.  IP‐10 predicts viral response and therapeutic outcome in difficult‐to‐treat patients with HCV genotype 1 infection , 2006, Hepatology.

[35]  Peter Vandenabeele,et al.  Necrosis, a well-orchestrated form of cell demise: signalling cascades, important mediators and concomitant immune response. , 2006, Biochimica et biophysica acta.

[36]  J. Olynyk,et al.  Antiproliferative effects of interferon alpha on hepatic progenitor cells in vitro and in vivo , 2006, Hepatology.

[37]  S. Kelsen,et al.  CXCR3 surface expression in human airway epithelial cells: cell cycle dependence and effect on cell proliferation. , 2006, American journal of physiology. Lung cellular and molecular physiology.

[38]  J. Hayashi,et al.  A comparison of the antitumor effects of interferon-α and β on human hepatocellular carcinoma cell lines , 2006 .

[39]  J. Hayashi,et al.  A comparison of the antitumor effects of interferon-alpha and beta on human hepatocellular carcinoma cell lines. , 2006, Cytokine.

[40]  Rakesh K. Kumar,et al.  Expression of the chemokine IP‐10 (CXCL10) by hepatocytes in chronic hepatitis C virus infection correlates with histological severity and lobular inflammation , 2003, Journal of leukocyte biology.

[41]  J. Lippincott-Schwartz,et al.  Measuring Protein Mobility by Photobleaching GFP Chimeras in Living Cells , 2003, Current protocols in cell biology.

[42]  T. Taniguchi,et al.  New aspects of IFN‐α/β signalling in immunity, oncogenesis and bone metabolism , 2003 .

[43]  T. Taniguchi,et al.  New aspects of IFN-alpha/beta signalling in immunity, oncogenesis and bone metabolism. , 2003, Cancer science.

[44]  K. Honda,et al.  Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. , 2003, Nature.

[45]  K. Schulze-Osthoff,et al.  Apoptosis in hepatitis C virus infection , 2003, Cell Death and Differentiation.

[46]  J. Lippincott-Schwartz,et al.  Studying protein dynamics in living cells , 2001, Nature Reviews Molecular Cell Biology.

[47]  A. Levine,et al.  Surfing the p53 network , 2000, Nature.

[48]  W. Fiers,et al.  More than one way to die: apoptosis, necrosis and reactive oxygen damage , 1999, Oncogene.

[49]  R. Silverman,et al.  A dominant negative mutant of 2‐5A‐dependent RNase suppresses antiproliferative and antiviral effects of interferon. , 1993, The EMBO journal.

[50]  K. Orita,et al.  A comparison of the antitumor effects of natural human tumor necrosis factors alpha and beta: the roles of arachidonic acid metabolism and intracellular cAMP. , 1990, Japanese journal of clinical oncology.

[51]  B. Williams,et al.  Constitutive expression of a 2',5'-oligoadenylate synthetase cDNA results in increased antiviral activity and growth suppression. , 1989, Journal of interferon research.